TAKAYASU ARTERITIS

This study is testing a live attenuated dengue vaccine (Butantan-DV) in people aged 12–59 with autoimmune rheumatic diseases like rheumatoid arthritis or lupus, who are stable and on low or no immune-suppressing drugs. Researchers want to see if the vaccine is safe and triggers a…

This study looks at whether people with Takayasu arteritis, a rare blood vessel disease, can stop taking biologic drugs after being in remission for a long time. About 40 participants who have been on biologics for at least 3 years will slowly reduce their dose over 3 months, the…

This study tests whether two medications, dapagliflozin and bosentan, can improve blood vessel function in people with large vessel vasculitis (LVV), a condition that damages arteries and raises the risk of heart attacks and strokes. About 60 adults with stable LVV will take both…

This study looks at how two rare diseases that cause blood vessel inflammation—Takayasu arteritis and Behçet's disease—affect physical strength, daily function, and emotional well-being. Researchers will compare 30 adults with these conditions to healthy volunteers using simple t…

This study uses two separate questionnaires to learn about the experiences of people with Takayasu arteritis (TAK) and how doctors manage the condition. About 50 patients and an unspecified number of physicians will share their views on symptoms, treatment priorities, and unmet n…

This study collects existing tissue samples from 1,000 people with various forms of vasculitis, a group of rare blood vessel diseases. Researchers will analyze the samples along with health data to find genes and other factors that cause these conditions. The goal is to spark new…